{"id":59245,"date":"2026-03-11T13:45:42","date_gmt":"2026-03-11T05:45:42","guid":{"rendered":"https:\/\/flcube.com\/?p=59245"},"modified":"2026-03-11T13:45:43","modified_gmt":"2026-03-11T05:45:43","slug":"astrazeneca-initiates-clarity-gastric-02-phase-iii-sonesitatug-vedotin-combo-triggers-45-million-milestone-from-kym-biosciences","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59245","title":{"rendered":"AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences"},"content":{"rendered":"\n<p><strong>AstraZeneca<\/strong> (AZ, <a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NASDAQ: AZN<\/a>) announced the <strong>initiation of CLARITY-Gastric 02<\/strong>, a <strong>multi-center, randomized, controlled Phase III study<\/strong> evaluating <strong>sonesitatug vedotin (AZD0901\/CMG901)<\/strong> in combination with <strong>capecitabine<\/strong>, with or without <strong>rilvegostomig<\/strong>, for <strong>first-line treatment<\/strong> of <strong>Claudin 18.2-positive, HER2-negative advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma<\/strong>. The <strong>first patient dosing<\/strong> triggered a <strong>$45\u202fmillion milestone payment<\/strong> to <strong>KYM Biosciences<\/strong> under the <strong>February 2023 global exclusive license agreement<\/strong>, validating the <strong>Claudin 18.2 ADC&#8217;s<\/strong> progression to <strong>registrational-stage development<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-trial-overview\">Clinical Trial Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Name<\/strong><\/td><td>CLARITY-Gastric 02<\/td><\/tr><tr><td><strong>Phase<\/strong><\/td><td>III (registrational)<\/td><\/tr><tr><td><strong>Design<\/strong><\/td><td>Multi-center, randomized, controlled<\/td><\/tr><tr><td><strong>Arms<\/strong><\/td><td>Sonesitatug vedotin + capecitabine \u00b1 rilvegostomig<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Claudin 18.2-positive, HER2-negative advanced\/metastatic gastric\/GEJ\/esophageal adenocarcinoma<\/td><\/tr><tr><td><strong>Setting<\/strong><\/td><td>First-line treatment<\/td><\/tr><tr><td><strong>Comparator<\/strong><\/td><td>Standard of care (likely platinum\/fluoropyrimidine chemotherapy)<\/td><\/tr><tr><td><strong>Milestone Trigger<\/strong><\/td><td>First subject dosed<\/td><\/tr><tr><td><strong>Milestone Amount<\/strong><\/td><td>$45 million (paid by AstraZeneca to KYM Biosciences)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Sonesitatug Vedotin (AZD0901\/CMG901) Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug Class<\/strong><\/td><td>Antibody-drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Claudin 18.2 (tight junction protein overexpressed in gastric\/GEJ cancer)<\/td><\/tr><tr><td><strong>Components<\/strong><\/td><td>\u2022 Claudin 18.2-specific antibody<br>\u2022 Cleavable linker<br>\u2022 Monomethyl auristatin E (MMAE) payload<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Targeted delivery of MMAE to Claudin 18.2-positive tumor cells; microtubule disruption; bystander effect<\/td><\/tr><tr><td><strong>Development Origin<\/strong><\/td><td>KYM Biosciences Inc. (joint venture: Lepu Biopharma + Keymed Biosciences)<\/td><\/tr><tr><td><strong>Global Rights<\/strong><\/td><td>AstraZeneca (exclusive out-license, February 2023)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Combination Rationale:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Capecitabine:<\/strong> Oral fluoropyrimidine backbone; synergistic with ADC payload<\/li>\n\n\n\n<li><strong>Rilvegostomig (optional):<\/strong> Anti-PD-1\/LAG-3 bispecific; immune checkpoint blockade enhances ADC-mediated anti-tumor immunity<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-amp-partnership-structure\">Transaction &amp; Partnership Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Element<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agreement Date<\/strong><\/td><td>February 2023<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>Global exclusive out-license<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>KYM Biosciences (Lepu Biopharma + Keymed Biosciences JV)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>AstraZeneca (development and commercialization)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>$63 million (2023)<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>&gt;$1.1 billion potential (development and sales-based)<\/td><\/tr><tr><td><strong>Current Milestone<\/strong><\/td><td>$45 million (Phase III initiation)<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered double-digit on net sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-context-amp-market-opportunity\">Strategic Context &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>Gastric Cancer Burden<\/strong><\/td><td>5th most common cancer globally; 1M+ annual deaths; Claudin 18.2 expressed in ~40% of gastric\/GEJ adenocarcinomas<\/td><\/tr><tr><td><strong>HER2-Negative Gap<\/strong><\/td><td>~60% of gastric cancers HER2-negative; no targeted first-line options beyond chemotherapy<\/td><\/tr><tr><td><strong>Claudin 18.2 Validation<\/strong><\/td><td>Zolbetuximab (Astellas) approved 2024 (mAb); ADC mechanism (sonesitatug) offers superior potency and bystander killing<\/td><\/tr><tr><td><strong>AstraZeneca Oncology<\/strong><\/td><td>Enhances GI cancer portfolio (Tagrisso, Imfinzi); leverages global commercial infrastructure<\/td><\/tr><tr><td><strong>Milestone Timing<\/strong><\/td><td>$45M payment validates Phase III commitment; additional milestones for regulatory approvals and sales thresholds<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitor<\/th><th>Product<\/th><th>Mechanism<\/th><th>Setting<\/th><th>Sonesitatug Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Astellas<\/strong><\/td><td>Vyloy (zolbetuximab)<\/td><td>Claudin 18.2 mAb<\/td><td>1L gastric (approved 2024)<\/td><td>ADC payload vs. ADCC; potential for combination superiority<\/td><\/tr><tr><td><strong>Amgen<\/strong><\/td><td>AMG 199<\/td><td>Claudin 18.2\/CD3 BiTE<\/td><td>Phase I<\/td><td>Later-stage development; established AstraZeneca infrastructure<\/td><\/tr><tr><td><strong>Keymed\/AZ<\/strong><\/td><td><strong>Sonesitatug vedotin<\/strong><\/td><td><strong>Claudin 18.2 ADC<\/strong><\/td><td><strong>Phase III (1L)<\/strong><\/td><td><strong>First-in-class ADC with capecitabine \u00b1 immunotherapy backbone<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Timeline<\/th><th>Objectives<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase III (CLARITY-Gastric 02)<\/strong><\/td><td>2026-2029<\/td><td>Overall survival primary endpoint; global enrollment (Asia, EU, U.S.)<\/td><\/tr><tr><td><strong>Regulatory Filing<\/strong><\/td><td>2029-2030<\/td><td>China NDA; U.S.\/EU BLA simultaneous submission<\/td><\/tr><tr><td><strong>Combination Expansion<\/strong><\/td><td>Ongoing<\/td><td>Rilvegostomig addition may support label differentiation vs. chemotherapy alone<\/td><\/tr><tr><td><strong>Biomarker Strategy<\/strong><\/td><td>2026+<\/td><td>Claudin 18.2 IHC companion diagnostic development and commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Phase III enrollment timelines, regulatory pathways, and milestone achievement for sonesitatug vedotin. Actual results may differ due to competitive dynamics with zolbetuximab, gastric cancer trial execution risks, and manufacturing scale-up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca (AZ, NASDAQ: AZN) announced the initiation of CLARITY-Gastric 02, a multi-center, randomized, controlled Phase&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[35,130,770,62,871],"class_list":["post-59245","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","category-drug","tag-adc-xdc","tag-astrazeneca","tag-az","tag-clinical-trial-approval-initiation","tag-nasdaq-azn"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"AstraZeneca (AZ, NASDAQ: AZN) announced the initiation of CLARITY-Gastric 02, a multi-center, randomized, controlled Phase III study evaluating sonesitatug vedotin (AZD0901\/CMG901) in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive, HER2-negative advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. The first patient dosing triggered a $45\u202fmillion milestone payment to KYM Biosciences under the February 2023 global exclusive license agreement, validating the Claudin 18.2 ADC&#039;s progression to registrational-stage development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59245\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca (AZ, NASDAQ: AZN) announced the initiation of CLARITY-Gastric 02, a multi-center, randomized, controlled Phase III study evaluating sonesitatug vedotin (AZD0901\/CMG901) in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive, HER2-negative advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. The first patient dosing triggered a $45\u202fmillion milestone payment to KYM Biosciences under the February 2023 global exclusive license agreement, validating the Claudin 18.2 ADC&#039;s progression to registrational-stage development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59245\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-11T05:45:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-11T05:45:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59245#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59245\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences\",\"datePublished\":\"2026-03-11T05:45:42+00:00\",\"dateModified\":\"2026-03-11T05:45:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59245\"},\"wordCount\":510,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"AstraZeneca\",\"AZ\",\"Clinical trial approval \\\/ initiation\",\"NASDAQ: AZN\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59245#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59245\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59245\",\"name\":\"AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-11T05:45:42+00:00\",\"dateModified\":\"2026-03-11T05:45:43+00:00\",\"description\":\"AstraZeneca (AZ, NASDAQ: AZN) announced the initiation of CLARITY-Gastric 02, a multi-center, randomized, controlled Phase III study evaluating sonesitatug vedotin (AZD0901\\\/CMG901) in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive, HER2-negative advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. The first patient dosing triggered a $45\u202fmillion milestone payment to KYM Biosciences under the February 2023 global exclusive license agreement, validating the Claudin 18.2 ADC's progression to registrational-stage development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59245#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59245\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59245#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences - Insight, China&#039;s Pharmaceutical Industry","description":"AstraZeneca (AZ, NASDAQ: AZN) announced the initiation of CLARITY-Gastric 02, a multi-center, randomized, controlled Phase III study evaluating sonesitatug vedotin (AZD0901\/CMG901) in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive, HER2-negative advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. The first patient dosing triggered a $45\u202fmillion milestone payment to KYM Biosciences under the February 2023 global exclusive license agreement, validating the Claudin 18.2 ADC's progression to registrational-stage development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59245","og_locale":"en_US","og_type":"article","og_title":"AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences","og_description":"AstraZeneca (AZ, NASDAQ: AZN) announced the initiation of CLARITY-Gastric 02, a multi-center, randomized, controlled Phase III study evaluating sonesitatug vedotin (AZD0901\/CMG901) in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive, HER2-negative advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. The first patient dosing triggered a $45\u202fmillion milestone payment to KYM Biosciences under the February 2023 global exclusive license agreement, validating the Claudin 18.2 ADC's progression to registrational-stage development.","og_url":"https:\/\/flcube.com\/?p=59245","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-11T05:45:42+00:00","article_modified_time":"2026-03-11T05:45:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59245#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59245"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences","datePublished":"2026-03-11T05:45:42+00:00","dateModified":"2026-03-11T05:45:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59245"},"wordCount":510,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","AstraZeneca","AZ","Clinical trial approval \/ initiation","NASDAQ: AZN"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59245#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59245","url":"https:\/\/flcube.com\/?p=59245","name":"AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-11T05:45:42+00:00","dateModified":"2026-03-11T05:45:43+00:00","description":"AstraZeneca (AZ, NASDAQ: AZN) announced the initiation of CLARITY-Gastric 02, a multi-center, randomized, controlled Phase III study evaluating sonesitatug vedotin (AZD0901\/CMG901) in combination with capecitabine, with or without rilvegostomig, for first-line treatment of Claudin 18.2-positive, HER2-negative advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. The first patient dosing triggered a $45\u202fmillion milestone payment to KYM Biosciences under the February 2023 global exclusive license agreement, validating the Claudin 18.2 ADC's progression to registrational-stage development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59245#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59245"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59245#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"AstraZeneca Initiates CLARITY-Gastric 02 Phase III \u2013 Sonesitatug Vedotin Combo Triggers $45\u202fMillion Milestone from KYM Biosciences"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59245"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59245\/revisions"}],"predecessor-version":[{"id":59246,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59245\/revisions\/59246"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}